Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival.

Saved in:

Bibliographic Details
Title:	Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival.
Authors:	De Leo S; Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy., Di Stefano M; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy., Persani L; Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy.; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy., Fugazzola L; Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy. laura.fugazzola@unimi.it.; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. laura.fugazzola@unimi.it., Colombo C; Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Source:	Endocrine [Endocrine] 2021 May; Vol. 72 (2), pp. 462-469. Date of Electronic Publication: 2020 Sep 03.
Publication Type:	Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Springer Country of Publication: United States NLM ID: 9434444 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-0100 (Electronic) Linking ISSN: 1355008X NLM ISO Abbreviation: Endocrine Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1559-0100
DOI:	10.1007/s12020-020-02477-0